What Happens If You Miss a Dose of Estradiol

Per FDA-approved labeling for commercial estradiol products, if a dose is missed, the appropriate next step depends on the delivery form (pill, patch, gel, implant, injection, or vaginal form) and how long it has been since the missed dose. Per FDA-approved labeling for commercial estradiol products, a single missed dose may be associated with return of menopausal symptoms such as hot flashes or sleep disturbance; individual responses vary. Patients should contact their prescriber if doses are missed repeatedly or if symptoms change.

Below is a practical, clear plan by formulation and what to watch for. The goals are to restore the routine as directed, protect the uterine lining if a progestogen is also used, and know when to call a clinician. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.

How to handle a missed estradiol dose

• Oral daily tablets: Per FDA-approved labeling for commercial oral estradiol products, the missed-dose instruction is to take the dose as soon as it is remembered, if it is the same day or within approximately 24 hours. FDA-approved labeling for commercial oral estradiol products states that, if more than approximately 24 hours have passed, the missed tablet should be skipped and the next one taken at the usual scheduled time. Double doses should not be taken unless directed by a prescriber. Per FDA-approved labeling for commercial oral estradiol products, a single missed tablet may be associated with return of mild menopausal symptoms such as hot flashes or sleep disturbance; individual responses vary. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.
• Transdermal patch (weekly or twice-weekly): Per FDA-approved labeling for commercial estradiol patch products, if the patch came off or application was missed and it is noticed within 24 hours, the labeled guidance is that the same patch may be reapplied or a new one applied and the usual schedule continued. FDA-approved labeling for commercial estradiol patch products states that, if more than 24 hours have passed, a new patch may be applied and the weekly schedule restarted. Two patches should not be applied at once unless directed by a prescriber. Patients who are uncertain about timing should contact their prescriber to discuss whether the current regimen remains appropriate. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.
• Gel or spray (daily): Per FDA-approved labeling for commercial topical estradiol products, the missed-dose instruction is to apply as soon as it is remembered if it is within the same day. FDA-approved labeling for commercial topical estradiol products states that, if the next scheduled dose is close, the missed application should be skipped and the normal routine resumed. Extra doses should not be applied unless directed by a prescriber. Per FDA-approved labeling for commercial topical estradiol products, a missed application may be associated with a return of symptoms in some patients; individual responses vary. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.
• Long-acting injections or implants: A missed injection cannot be replaced at home. Patients should contact their clinician promptly; a short delay of days may be acceptable depending on the regimen, but timing matters because these forms may be used to help maintain steadier hormone levels. A prescriber will advise on the appropriate next step. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.
• Vaginal estradiol (local): Per FDA-approved labeling for commercial vaginal estradiol products, if a dose is missed, the labeled guidance is to insert or apply as soon as it is remembered. An extra dose should not be used unless directed by a prescriber. Per FDA-approved labeling for commercial vaginal estradiol products, missing one dose may be associated with worsening vaginal dryness or recurrence of local symptoms in some patients; individual responses vary. Patients should contact their prescriber if local symptoms change or persist. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.
• If combined HRT with a progestogen is used: Per FDA-approved labeling for commercial estradiol products used in combination regimens, missing an estrogen dose may be associated with spotting or breakthrough bleeding on cyclical regimens. If there is uncertainty about how to adjust the progestogen schedule after a missed estrogen dose, a prescriber should be contacted. Progestogen should not be stopped without checking, because continuous progestogens are used to help protect the uterine lining. Patients should follow their prescriber's directions and the dispensing pharmacy's instructions for their specific product.

When to contact your prescriber: Per FDA-approved labeling for commercial estrogen-containing products, the FDA labeling describes symptoms such as new chest pain, leg swelling, severe headache, visual changes, unexpected heavy bleeding, and shortness of breath as serious events associated with commercial estrogen-containing products — including cardiovascular events, deep vein thrombosis (DVT), pulmonary embolism (PE), endometrial cancer, breast cancer, and probable dementia in women 65 and older. These data reflect the safety profile of FDA-approved commercial estrogen products and should not be assumed to define the safety profile of any compounded preparation; compounded preparations differ in formulation and regulatory status. Patients who experience any of these symptoms should contact their prescriber promptly. Whether any individual symptom warrants intervention depends on personal health factors that a clinician must assess, and published guidance from NAMS or ACOG informs how prescribers evaluate them. Patients should also contact their prescriber for repeated missed doses, uncertainty about combined HRT rules, or if symptoms change. Per FDA-approved labeling for commercial estradiol products, one missed dose is generally addressed by taking the missed dose if it is recent, or resuming the schedule as directed; per FDA-approved labeling for commercial estradiol products, menopausal symptoms may be associated with gradual return if doses are missed regularly, with individual responses varying. This information reflects FDA-approved labeling for commercial estradiol products and does not establish the safety, effectiveness, or labeling status of any compounded preparation; compounded preparations differ in formulation and regulatory status and should be used only as directed by the prescriber and the dispensing pharmacy.